Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Brad H. Rovin(The Ohio State University Wexner Medical Center), Catarina Almeida, Ulysses Diva(Korean Red Cross), Roberta Aliotta, Michelle N. Rheault(Columbia University Irving Medical Center), Dong-Wan Chae(Korean Red Cross), William E. Rote(Therapeutics Clinical Research), Laura Kooienga(Therapeutics Clinical Research), Syeda B. Ahmad, Charles E. Alpers(University of Washington), Wooin Ahn, Vlado Perkovic(New South Wales Department of Health), Howard Trachtman(University of Michigan), Irene L. Noronha(Universidade de São Paulo), Hiddo J.L. Heerspink(University Medical Center Groningen), Robert Małecki(Międzyleski Szpital Specjalistyczny w Warszawie), Bassam Alchi, Bamidele Ajayi, Catarina Abrantes, Priscila Preciado(Research Institute Hospital 12 de Octubre), Muh Geot Wong(FIND), Jula K. Inrig(Duke University), Annika Adoberg, Isabella Abbasciano(UNSW Sydney), É. Alamartine, Simone Accarino, Manuel Praga(Universidad Complutense de Madrid), Jonathan Barratt(University of Leicester), Rouzbeh Afsari, Salem Almaani, Sharon G. Adler(UCLA Medical Center), Chen Au Peh(Royal Adelaide Hospital), Jafar Ahmed, Richard Lafayette(Stanford Medicine), Saif Al‐Chalabi, Radko Komers(University of Utah), Donald E. Kohan(University of Utah), Hernán Trimarchi(University of Michigan), Vladimı́r Tesař(Charles University), Dariusz Aksamit, Bart Maes(AZ Delta), Se Won Oh(Korea University), Stewart Bieler(University of Washington), Jai Radhakrishnan(Columbia University), Mohammad Ali, Sydney Tang(Chinese University of Hong Kong), James A. Tumlin(Emory University), Jürgen Floege(RWTH Aachen University), Alex Mercer(Innovation Management Consulting Group (Sweden)), Loreto Gesualdo(Unknown)
Cited by 264
Related Papers
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Worldwide access to treatment for end-stage kidney disease: a systematic review
|The Lancet|2015|2.3k